GlassScriptPhysician profile
Nathaniel R Ranney
NPI 1366676223
$391,829.84
in general payments reported to CMS, 2019-2025
51 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44K · 2020: $12K · 2021: $49K · 2022: $73K · 2023: $62K · 2024: $79K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $178K · Consulting Fee: $14K · Travel and Lodging: $12K · Food and Beverage: $11K · Education: $34.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $177,625.00 |
| Consulting Fee | $13,550.00 |
| Travel and Lodging | $12,354.12 |
| Food and Beverage | $10,966.88 |
| Education | $34.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $377,826.92 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,517.15 | 2019-2025 | Xifaxan, Relistor |
| Janssen Biotech, INC. | $1,336.07 | 2019-2025 | Stelara, Tremfya, Simponi |
| Medtronic USA, INC. | $1,185.56 | 2020 | |
| Celgene Corporation | $1,156.31 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,099.10 | 2019-2025 | Entyvio, Eohilia |
| Gilead Sciences, INC. | $979.83 | 2019-2025 | |
| Allergan, INC. | $975.80 | 2019-2020 | |
| Pfizer INC. | $929.56 | 2019-2025 | |
| Qol Medical, LLC | $710.49 | 2019-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $425.35 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $398.58 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $308.30 | 2019-2024 | |
| Ironwood Pharmaceuticals, INC | $291.23 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $182.41 | 2019-2024 | Dificid |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $165.67 | 2019-2020 | |
| Celltrion USA INC. | $164.99 | 2024-2025 | Vegzelma, Zymfentra |
| Boston Scientific Corporation | $164.22 | 2020-2023 | Resolution 360 Ultra Clip, Captivator II |
| Lilly USA, LLC | $152.35 | 2024-2025 | Omvoh |
| Conmed Corporation | $150.72 | 2020-2021 | |
| Redhill Biopharma INC. | $142.09 | 2020-2023 | Aemcolo, Talicia, Movantik |
| Medtronic, INC. | $129.71 | 2021-2023 | Bravo |
| Regeneron Healthcare Solutions, INC. | $125.50 | 2024-2025 | Dupixent |
| Evoke Pharma, INC. | $121.31 | 2020-2024 | Gimoti |
| Ferring Pharmaceuticals INC. | $110.49 | 2019-2022 | |
| Braintree Laboratories, INC. | $108.81 | 2019-2025 | Suflave, Sutab |
| Daiichi Sankyo INC. | $107.02 | 2019-2024 | Injectafer |
| Shionogi INC | $100.18 | 2019 | |
| Phathom Pharmaceuticals, INC. | $83.42 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $80.64 | 2025 | Zenpep, Vowst |
| Intra-Sana Laboratories | $71.08 | 2025 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Endo Pharmaceuticals INC. | $65.53 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $59.80 | 2025 | Iqirvo |
| Pharmacosmos Therapeutics INC. | $49.00 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.99 | 2023 | Cyltezo |
| Pentax of America, INC. | $39.68 | 2022 | |
| Exact Sciences Corporation | $35.19 | 2024-2025 | Cologuard Collection Kit |
| Biocon Biologics INC | $32.89 | 2024-2025 | Yesintek, Hulio |
| Madrigal Pharmaceuticals | $26.50 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2021 | |
| Amgen INC. | $22.80 | 2023 | Amjevita, Avsola |
| Axonics, INC. | $18.47 | 2021 | |
| Alexion Pharmaceuticals, INC. | $16.96 | 2020 | |
| Steris Corporation | $16.79 | 2020 | |
| Novo Nordisk INC | $16.51 | 2025 | Wegovy |
| Cook Medical LLC | $14.19 | 2025 | Echotip Insight |
| Covidien LP | $13.26 | 2019 | |
| Shire North American Group INC | $13.23 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.05 | 2022 | |
| Organon LLC | $5.90 | 2023 | Hadlima |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$20,648.97 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathaniel Ranney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.